Baseline demographics of 420 patients with PsA, subdivided by anti-TNF drug. All data are median (range) unless otherwise indicated.
| All, n = 420 | ADA, n = 139 | ETN, n = 197 | IFX, n = 84 | p | |
|---|---|---|---|---|---|
| Age, yrs | 50 (16–81) | 46 (18–72) | 51 (16–81) | 50 (16–77) | 0.24 |
| Duration, yrs | 4 (0.8–39) | 3.3 (0.8–37) | 3.0 (0.3–35) | 4.5 (0.4–39) | 0.32 |
| ESR, mm/h | 16 (2–97) | 13 (2–90) | 16 (2–97) | 22 (2–90) | 0.03 |
| CRP, mg/dl | 0.4 (0.1–14) | 0.3 (0.1–12) | 0.4 (0.1–14) | 0.5 (0.1–10) | 0.04 |
| 68-TJC | 7 (1–59) | 7 (1–57) | 7 (1–59) | 8 (1–47) | 0.70 |
| 66-SJC | 1 (0–42) | 1 (0–42) | 1 (1–36) | 2 (1–33) | 0.84 |
| DAS28 | 4.3 (1.4–8.6) | 4.1 (1.4–7.1) | 4.2 (1.6–8.6) | 4.8 (1.8–8.4) | 0.02 |
| HAQ | 1.12 (0.1–3.0) | 1.12 (0.1–2.75) | 1.12 (0.1–3.0) | 1.25 (0.1–3.0) | 0.81 |
| VAS-Pain | 70 (10–100) | 60 (10–100) | 70 (10–100) | 70 (10–100) | 0.55 |
| PtGA | 70 (10–100) | 60 (10–100) | 70 (10–100) | 70 (10–100) | 0.06 |
| PASI | 1.2 (0–47) | 1.2 (0–47) | 0.8 (0–18) | 6.3 (0–14) | 0.01 |
| Predn (mg/day) | 5.0 (2.5–25) | 5.0 (2.5–10) | 5.0 (2.5–15) | 5.0 (2.5–25) | 0.08 |
| Female, n (%) | 257 (61) | 85 (61) | 122 (62) | 50 (60) | 0.91 |
| CRP > 1, n (%) | 110 (29) | 28 (23) | 53 (28) | 29 (37) | 0.14 |
| Predn, n (%) | 204 (50) | 67 (50) | 102 (52) | 35 (43) | 0.38 |
| DMARD, n (%) | 245 (60) | 87 (64) | 106 (54) | 52 (64) | 0.11 |
PsA: psoriatic arthritis; TNF: tumor necrosis factor; ADA: adalimumab; ETN: etanercept; IFX: infliximab; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28: 28-joint Disease Activity Score; 68-TJC: 68 joint tender joint count; 66-SJC: 66 joint swollen joint count; VAS: visual analog scale; HAQ: Health Assessment Questionnaire; PtGA: patient’s global assessment of disease activity; PASI: Psoriasis Area and Severity Index; DMARD: disease-modifying antirheumatic drugs; Predn: prednisone.